Active, Not Recruiting
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Research Site Beijing, China
- Research Site Beijing, China
- Research Site Beijing, China
- Research Site Chengdu, China